Overview

Discovery Stage IND EXEMPT Clinical Study About ABIRATERONE ACETATE and Single Nucleotide Polymorphisms

Status:
Active, not recruiting

Trial end date:
2022-08-28

Target enrollment:

Participant gender:

Summary

That current oncology drugs on USA market have the universal problems about low effectiveness of pharmacology to cancer cells and high risk of toxicology to normal cells can demonstrate following most significantly and most reasonably: it is not enough so far away that just only oncology drug target molecules as cancer patient-specific biomarkers directly; it must be that oncology drug targets' SNPs like as real personalized or individualized cancer patient-specific biomarkers.

Phase:

Phase 3

Details

Lead Sponsor:

Dr. Han Xu, President/CEO / PD / PI / Monitor / IRB Chair
Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair

Collaborator:

PPD

Treatments:

Abiraterone Acetate
Leuprolide
Nilutamide
Prednisone
Triptorelin Pamoate